tirzepatide and sleep apnea for the treatment of obstructive obesity Apnea: An Evolving Therapeutic Landscape with an Emerging Role Incretin-Based Therapies How Tirzepatide Helps Treat Sleep

Standard GLP-1 eligibility thresholds - based on the FDA-approved drug labeling for Wegovy and Zepbound, which guides how clinicians think about the category - generally include a BMI of 30 or higher (obese), or a BMI of 27 or higher with at least one weight-related comorbidity such as high blood pressure, high cholesterol, or type 2 diabetes

Its important to understand that not all drugs with the word sulfa in their name are the same, and not all cause allergic reactions

Yamamoto N, Ishikuro R, Tanida M, Suzuki K, Ikeda-Matsuo Y, Sobue K

The challenge isn't knowing you should drink more water

Under a licensing and collaboration deal with Yuhan Corp